Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Number of holders
-
22
-
Total 13F principal, excl. options
-
92.3M
-
Principal change
-
+11.7M
-
Total reported value, excl. options
-
$90.8M
-
Value change
-
+$10.6M
-
Number of buys
-
9
-
Number of sells
-
-5
-
Price
-
$0.98
Significant Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q4 2022
24 filings reported holding 45845PAA6 - INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q4 2022.
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 has 22 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $92.3M of principal
.
Largest 10 bondholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) ($57.8M of principal), Kohlberg Kravis Roberts & Co. L.P. ($13M of principal), OAKTREE CAPITAL MANAGEMENT LP ($10.7M of principal), Atlas Merchant Capital LLC ($3.5M of principal), Russell Investments Group, Ltd. ($2.32M of principal), MORGAN STANLEY ($1.46M of principal), PIPER SANDLER & CO. ($1.16M of principal), L & S Advisors Inc ($795K of principal), STATE STREET CORP ($521K of principal), and GAMCO INVESTORS, INC. ET AL ($250K of principal).
This table shows the top 22 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.